Psychedelic Therapy Offers New Hope for Veterans Battling PTSD, Suicidal Ideation

After enduring years of battling the shadows of PTSD from his combat tours in Iraq and Afghanistan, retired Green Beret Joe Hudak found himself on the brink of despair, contemplating the unthinkable. Conventional treatments had proven ineffective, and the shadows within his thoughts became increasingly overwhelming. In a moment that would change everything, a former counterterrorism teammate reached out with a bold proposal: explore the world of psychedelics.

Hudak embarked on a journey to Mexico to take part in a Stanford-led observational study exploring the use of ibogaine, a potent plant-derived psychedelic, aimed at addressing PTSD, depression, and anxiety among Special Forces veterans. With a single dose, he claims, the persistent whisper in his mind was finally quieted. “It was a turning point for me,” he remarked.

A recent study from Stanford, co-led by neuropsychiatrist Dr. Ian Kratter, revealed a remarkable average reduction of 88% in PTSD symptoms within just a month of treatment, with comparable declines observed in depression and anxiety as well. Another participant, Sean, recounted a complete transformation of his emotional landscape. “I just felt whole again,” he reflected, acknowledging the clarity and renewed sense of self that had emerged since the treatment.

The nonprofit organization Veterans Exploring Treatment Solutions (VETS) sponsored Hudak’s journey, aiding over 1,000 veterans in seeking psychedelic therapies beyond U.S. borders, and is now advocating for transformative change domestically. They are concentrating on Assembly Bill 1103, a measure designed to simplify the approval process for academic research related to psychedelics in California.

Under the existing federal framework, psychedelics such as ibogaine are categorized as Schedule I substances, deemed to have no recognized medical application. However, emerging research reveals encouraging outcomes for conditions like PTSD, traumatic brain injuries, and treatment-resistant depression. AB 1103 would enable FDA-compliant studies to circumvent the extra regulatory delays imposed by California.

The legislative initiative emerges against a backdrop of troubling statistics, with 17.6 veterans tragically taking their own lives each day in 2022. “If assistance arrives promptly for even a single veteran, it holds great value for us,” stated Khurshid Khoja, VETS policy director.

Support is emerging from unexpected places: In a significant move, Texas has given the green light to a $50 million fund, supported by VETS, aimed at advancing psychedelic drug development. This initiative has garnered attention from former Governor Rick Perry, an Air Force veteran, who highlighted the transformative and life-saving potential of ibogaine.

As support from both sides of the aisle grows and the stakes rise, advocates are filled with optimism that psychedelic-assisted therapy could soon become a lawful and regulated choice for veterans across the United States.

‍